We are investigating the binding of a series of monoclonal antibodies to native and detergenttreated human T-lymphotropic virus I (HTLV-I) envelope proteins to explore their conformation. A comparison of our data with previously published findings suggests that a central neutralization domain (aa 175-200) is folded such that only short stretches are exposed at the surface of the native envelope protein complex. However, the complete domain becomes accessible after treatment with mild non-ionic detergents, suggesting that envelope subunit interaction may partially obscure this domain. We further provide immunochemical evidence that a region containing a heptad repeat in the extracellular part of the transmembrane protein is folded towards the interior of the HTLV-I envelope complex.
The human T-lymphotropic virus type I (HTLV-I) env gene encodes a 61-69 kDa glycoprotein which is cleaved by cellular proteases to yield a 46 kDa surface glycoprotein (gp46; SU) and a 21kDa transmembrane glycoprotein (gp21; TM) (Hattori et al., I984; Lee eta] ., I984). The SU and TM proteins interact to form dimers, which aggregate into higher order oligomers (Paine et al., 1994) . While most SU and TM proteins are non-covalently associated, a small proportion may be covalently linked by an interchain disulphide bridge (Pique et al., 1992) . To begin to understand the tertiary structure of HTLV-I envelope glycoproteins, six of our own monoclonal antibodies (MAbs) (2.1e, 2.30g, 42a, 69b, 5a and 39b; Author for correspondence: C. V. F. Carrington. Carrington et al., 1994) , and two other previously published antibodies, 1Cll (Palker et a] ., 1989) and 0.5~ (Matsushita et al., 1986; Ralston et al., 1989) , were used to identify hidden and exposed regions on native and mildly denatured envelope glycoprotein. None of these antibodies were neutralizing in syncytium inhibition assays (data not shown).
The binding sites of our antibodies were mapped using 89 overlapping peptides [10-mers overlapping by five amino acids (aa)] covering gp46 and the extracellular region of gp21 (aa 1-450) which were synthesized on a membrane using a SPOTs analysis kit (Cambridge Research Biochemicals). MAbs were assayed for binding to individual peptides (or SPOTs) according to the manufacturer's instructions. Binding was detected with fi-galactosidase-conjugated anti-rat IgG. SPOTs positive for binding stained blue on incubation with flgalactosidase substrate (X-Gal). We also employed four overlapping 20-mers (PEP335-338) covering aa 171-220 in Env and a 16-mer covering aa 184-199 (peptide A) to map the epitopes for some of the antibodies by ELISA. Immulon 2 ELISA plates were coated overnight at room temperature with 10 ~g/ml peptide in 100 B1 coupling buffer (100 raM-sodium bicarbonate pH 8"5). Antibody binding to the peptides was then measured by conventional ELISA using an alkaline phosphatase-conjugated secondary antibody and the AMPAK detection system as previously described by Moore et al., (1989) . Table I summarizes the results from the ELISA (A49 ~ values) and SPOTs analysis (intensity of staining was scored visually), and the epitopes defined. MAb 39b which was raised to a recombinant E. coil fragment covering aa 348-442 (extracellular region of TM) failed to bind to any of the peptides suggesting that it recognizes a conformationally sensitive epitope.
The epitopes deduced for 2.30g and 2.1e overlap to a large extent, however their differential binding to peptides A, 37 and 39 suggests that the 2.1e binding site is slightly aminoterminal to that of 2.30g. Similarly the binding of 1Cli and 42a to PEP337 suggests that the 42a epitope overlaps with, but extends further C-terminal to the 1CI1 epitope. Using these peptides we also mapped the epitopes for MAbs 0.Sa and 1Cll to between aa 184-199, in good agreement with the previously reported epitopes for 0.Sa All the antibodies described bound specifically and equally well to the membranes of acetone-fixed HTLV-I-producer cell lines (MT2 and C91/PL) as measured by indirect immunofluorescence (not shown). However, when indirect immunofluorescence was performed on live cells, differential binding was observed (Fig. 1) . MAbs 69b, 1Cli (anti-SU) and 39b (anti-TM) bound to the MT2 and C91/PL cells indicating that their epitopes were all exposed on native envelope glycoprotein at the cell surface. A neutralizing MAb to a wider region containing the 69b epitope (aa 296-300) has been reported previously (Baba et al., 1993) suggesting that its epitope is also accessible at the cell surface. In contrast to 69b, 1Cll, and 39b, MAbs 5a (anti-TM), 42a, 2.1e and 2.30g (anti-SU) did not bind to MT2 cells. MAbs 5a and 2.1e also did not bind to C91/PL cells, whereas 2.30g and 42a showed an intermediate level of binding. This suggests that these epitopes are totally or at least partially hidden at the cell surface, with some minor variability between HTLV-I strains.
Although the conformationally sensitive epitope in the extracellular region of gp2i recognized by MAb 39b is exposed on the surface of C91/PL and MT2 cells, we have previously reported that this epitope is not accessible on a nonfusogenic HTLV-I-producer cell line C10/MJ2 expressing truncated HTLV-I TM protein lacking the hydrophobic membrane anchor (Carrington et aI., 1994) . Interestingly, we have observed that this is also not exposed on several stable transfectants of the HTIOSO/PL HTLV-I-producer cell line which, in spite of expressing full-length envelope proteins, have lost their ability to induce syncytium formation (C. V. F. Carrington, unpublished observations). Expression of this epitope on the surface of HTLV-I-infected cell lines may therefore indicate a functional envelope protein.
Although 'hidden' on the cell surface, the 2.30g epitope is as accessible as the 69b epitope ('exposed' epitope) on mildly denatured envelope glycoproteins. This was demonstrated by the equal ability of antibodies 2.30g and 69b coated onto Immulon 2 ELISA plates (Dynatech) at 5 ,g/ml to capture HTLV-I virions (from the MT2 cells), which had been solubilized in several mild non-ionic detergents (NP-40, Empigen, Brij 35, N-octoglucoside) (Fig. 2 a) . This suggests that a very mild disruption of the envelope conformation, possibly dissociation of the multimeric envelope protein complex exposes the epitope for MAb 2.30g. Equivalent results were obtained with HTLV-I virions purified from the non-fusogenic cell line CIO/MJ2 (data not shown). For these ELISAs the binding of envelope proteins to 2.30g and 69b was detected by HTLV-I-posffive serum and alkaline phosphatase-conjugated anti-human IgG and measured using the AMPAK detection system (Moore et al., 1989) . Virions used were pelleted from MT2 cell supernatants by centrifugation at 41000 r.p.m, in a '.02~ Beckman SW28 rotor for 2 h as described in Carrington et al. (1994) then allowed to resuspend overnight at 4 °C in PBS containing 0"1% detergent.
We also investigated the binding of the antibodies to recombinant envelope proteins produced in insect cells (Sf9) using a baculovirus expression system and in mammalian cells (BHK) using recombinant Semliki Forest virus vectors as described for human immunodeficiency virus type 1 (HIV-1) gp120 (Paul et al., 1993) . Cells expressing recombinant envelope proteins were pelleted and solubilized in PBS containing 1% Empigen, I mM-PMSF and 2 mM-EDTA then cleared extracts were serially diluted in PBS/0"5 % Empigen. The ability of MAbs to capture recombinant gp62 in the diluted extracts was measured in a capture ELISA as for envelope proteins extracted from gradient-purified virions (Fig. 2 b) .
Antibodies to both 'hidden' and 'exposed' epitopes captured insect cell and mammalian recombinant gp62 again suggesting that epitopes which are 'hidden' on native HTLV-I envelope glycoproteins are exposed on non-ionic detergenttreated recombinant envelope protein. MAb 42a bound significantly less well to mammalian gp62 than the others, but did recognize insect cell-produced gp6Z. MAb 42a which was raised against peptide A also bound better to this peptide than to recombinant insect cell-derived gp62 (not shown) indicating its preferential reactivity with denatured gp62.
The 'hidden' epitope for antibody 5a (aa 356-365) lies within a region of TM (aa 340-382) containing a heptad repeat which is conserved in a number of retroviruses (Delwart et al., 1990) . In HIV it has been implicated in fusion and infectivity (Dubay et al., 1992; Wild et a] ., 1992; Chen eta] ., 1993). The corresponding region in influenza virus HA2 is involved in coiled-coil formation during pH-induced activation of HA2 prior to fusion (Carr & Kim, 1993) . The 5a epitope includes an isoleucine residue (bold type in Table I ) which could be hidden if it formed part of a coiled-coil structure. It is possible however, that the 5a epitope is hidden by the SU protein. Sattentau et a] . (1995) have demonstrated that most of the extracellular portion of gp41 on the surface of HIV-l-infected cells and in virions is hidden in the presence of gp120 and only becomes exposed after interaction with CD4.
Antibodies 2.30g, 2.1e, 42a and 1Cli all map within a previously described neutralization domain (aa 175-200) of the HTLV-I envelope protein. Previous reports have defined two neutralizing epitopes within this domain, recognized, Fig. 2 . Antibody capture of detergent-solubilized virions and HTLV-I recombinant envelope glycoproteins. Envelope capture of (a) detergentsolubilized virions or (b) recombinant envelope glycoprotein using Immulon 2 ELISA plates (Dynatech) coated with 5 p.g/ml antibodies 5a (11), 69b (0), 42a (0), 2.309 (A) and 39b ([q) . The binding of envelope proteins in serially diluted extracts was detected by HTLV-Ipositive serum and alkaline phosphatase-conjugated anti-human IgG and measured using the AMPAK detection system as previously described by Moore et al. (1989) . ( 
Epitopes defined by synthetic peptides 186-190 180-190 184-199 184-199 191-199 290-300 350-365 * Other membrane bound peptides to which none of the antibodies bound are not shown. l-Membrane bound peptides (SPOTs) to which antibodies bind stain blue after addition of the p-galactosidase-conjugated secondary antibody and incubation with X-Gal substrate. The staining intensity was scored visually. NO, Not done.
respectively, by MAbs KE36-11 (aa I87-193) (Kuroki et al., 1992) and (Tanaka et al., 1994) . Such antigenic determinants recognized by neutralizing antibodies are exposed on the surface of HTLV-I-producer cell lines. However, although the epitopes recognized by 2.30g and 2.1e overlap with that of neutralizing antibodies of KE36-I 1 type, both 2.30g and 2.1e are non-neutralizing in our assays and do not bind to the surface of HTLV-I infected cell lines. In contrast, the epitopes for two non-neutralizing antibodies, 0.5c~ and 1Cll, although partially overlapping with those of 2.30g and 2.1e are exposed at the cell surface. Likewise the epitope defined by neutralizing antibodies of the LAT-2 7 type overlaps with 2.30g and 2.Ie but is exposed at the cell surface. However, nearly all antibodies used in this study bind efficiently to both virion-derived and recombinant HTLV-I envelope proteins after treatment with mild ionic detergents. These results suggest that this neutralizing domain between aa 175-200 is folded such that only short stretches are exposed at the surface of the HTLV-I envelope glycoprotein. This conformation is sensitive to mild ionic detergents. By analogy to the HIV-1 envelope glycoprotein complex, whose tetrameric structure is dissociated by such mild detergent treatment which does not affect the ability of the envelope subunit gp120 to bind soluble CD4 (Moore, 1990) , the interaction between gp46 subunits may determine the correct folding of the central neutralization domain.
